remikiren

Also Known As:

(S)-alpha-((S)-alpha-((t-butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; Ro 42-5892; Ro-42-5892; 1H-Imidazole-5-propanamide, N-((1R,2S,3R)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-a-(((2R)-3-((1,1-dimethylethyl)sulfonyl)-1-oxo-2-(phenylmethyl)propyl)amino)-, (aS)-

Networked: 15 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - remikiren: 15

Experts

1.	Bailly, Christian: 1 article (09/2021)
2.	Vergoten, Gérard: 1 article (09/2021)
3.	Navis, G: 1 article (05/2000)
4.	de Jong, P E: 1 article (05/2000)
5.	de Zeeuw, D: 1 article (05/2000)
6.	van Paassen, P: 1 article (05/2000)

Related Diseases

1.	Essential Hypertension 06/01/1996 - "Following a wash-out period of at least 3 weeks and then 8 days of single-blind placebo, 29 patients with essential hypertension were given remikiren 600 mg orally for 8 days. " 07/01/1995 - "In patients with essential hypertension, a single oral dose of remikiren can induce a renal vasodilation, without affecting the GFR and despite a significant decrease in blood pressure. " 02/01/1994 - "After three weeks of wash-out and one week of single-blind placebo run-in periods, 25 patients with mild to moderate essential hypertension (sitting DBP between 95 and 114 mmHg) were randomised to receive either placebo (n = 12) or 100 mg of Ro 42-5892 (n = 13) once daily for eight days. " 12/01/1999 - "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor remikiren could be predicted from pretreatment renal vascular tone. " 06/01/1996 - "Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. "
2.	Hypertension (High Blood Pressure) 12/01/1993 - "1 Three double-blind, randomized, placebo controlled, multiple oral dose studies in patients with mild to moderate hypertension were performed to study tolerability, pharmacodynamics and pharmacokinetics of remikiren. " 07/01/1991 - "When Ro 42-5892 was given, 1 mg/kg intravenously in 10 min, to subjects with hypertension, it appeared that plasma ANG I and II returned to baseline after 6-8 h, whereas PRA measured in the presence of PMSF and 8-OHQ was still suppressed. " 11/01/1993 - "Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension." 01/01/2022 - "By analogy, we postulated that the non-peptidic drug aliskiren, a more potent renin inhibitor than remikiren and a drug routinely used to treat hypertension, may also be able to interact with Mpro. "
3.	Proteinuria 05/01/2000 - "During remikiren, proteinuria fell by 27% (range -18 to -38%; P<0.01) in the patients with overt proteinuria at onset (n=6). " 01/01/1997 - "In the first study, six hospitalized patients (proteinuria 5.8 +/- 2.9 g/day) were treated with the renin-inhibitor remikiren 600 mg o.d. " 01/01/1997 - "Night-time proteinuria, however, was not significantly reduced from 0.23 +/- 0.11 to 0.19 +/- 0.11 g/h during remikiren and from 0.29 +/- 0.17 to 0.20 +/- 0.12 g/h during trandolapril. " 01/01/1997 - "Daytime proteinuria declined from 0.29 +/- 0.15 to 0.22 +/- 0.11 g/h (P < 0.05) during remikiren and from 0.33 +/- 0.14 to 0.16 +/- 0.08 g/h (P < 0.05) during trandolapril. "
4.	Heart Failure 12/01/1994 - "Thirty-six patients with chronic heart failure (New York Heart Association class II or III) were randomly assigned to receive double-blind either intravenous placebo, the renin inhibitor remikiren, or the converting enzyme inhibitor enalaprilat followed by coinfusion of a second placebo infusion, the addition of remikiren to enalaprilat, or the addition of enalaprilat to remikiren, respectively. "
5.	Exanthema (Rash) 02/01/1992 - "Thus, side effects such as rash, angioneurotic edema or cough, which have been attributed to bradykinin accumulation by ACE inhibitors, may not occur with the use of specific renin inhibitors such as Ro 42-5892."

Related Drugs and Biologics

1.	Renin Inhibitors
2.	Antihypertensive Agents (Antihypertensives)
3.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
4.	Enalaprilat (Vasotec)
5.	Dietary Sodium
6.	Renin
7.	Enzyme Inhibitors (Inhibitors, Enzyme)
8.	Enalapril
9.	Bradykinin
10.	Angiotensins

Related Therapies and Procedures

1.	Oral Administration